Overview

A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2302 vs. Tezspire in Healthy Subjects

Status:
NOT_YET_RECRUITING

Trial end date:
2026-09-01

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blinded, controlled Phase 1 study to compare the pharmacokinetic, safety and immunogenicity of QL2302 versus TezspireTezepelumab in healthy subjects after a single dose.

Phase:

PHASE1

Details

Lead Sponsor:

Qilu Pharmaceutical Co., Ltd.

Treatments:

tezepelumab